CureVac (NASDAQ:CVAC) Short Interest Update

CureVac (NASDAQ:CVAC - Get Free Report) was the recipient of a large growth in short interest in March. As of March 15th, there was short interest totalling 4,860,000 shares, a growth of 10.7% from the February 29th total of 4,390,000 shares. Currently, 5.3% of the company's shares are sold short. Based on an average daily trading volume, of 876,200 shares, the short-interest ratio is presently 5.5 days.

CureVac Trading Down 3.4 %

Shares of CureVac stock traded down $0.10 on Tuesday, reaching $2.88. 637,494 shares of the company's stock were exchanged, compared to its average volume of 793,478. CureVac has a 52 week low of $2.76 and a 52 week high of $12.36. The firm's 50-day moving average is $3.35 and its two-hundred day moving average is $4.64. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.56 and a quick ratio of 3.41.

Hedge Funds Weigh In On CureVac

A number of institutional investors have recently modified their holdings of the company. Vontobel Holding Ltd. raised its position in shares of CureVac by 3.8% during the first quarter. Vontobel Holding Ltd. now owns 19,411 shares of the company's stock worth $381,000 after purchasing an additional 702 shares during the period. Geode Capital Management LLC raised its position in shares of CureVac by 0.7% during the first quarter. Geode Capital Management LLC now owns 167,202 shares of the company's stock worth $1,165,000 after purchasing an additional 1,188 shares during the period. Citigroup Inc. raised its position in shares of CureVac by 10.2% during the second quarter. Citigroup Inc. now owns 13,491 shares of the company's stock worth $141,000 after purchasing an additional 1,253 shares during the period. Royal Bank of Canada raised its position in shares of CureVac by 13.0% during the third quarter. Royal Bank of Canada now owns 11,119 shares of the company's stock worth $87,000 after purchasing an additional 1,280 shares during the period. Finally, Marshall Wace LLP raised its position in shares of CureVac by 0.5% during the third quarter. Marshall Wace LLP now owns 333,819 shares of the company's stock worth $2,629,000 after purchasing an additional 1,758 shares during the period. 17.26% of the stock is owned by institutional investors and hedge funds.

CureVac Company Profile

CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.